The Food and Drug Administration Friday approved a new dosage option for buprenorphine and naloxone sublingual film, applied under the tongue as a maintenance treatment for opioid dependence. The medication-assisted treatment was approved through an abbreviated pathway under the Federal Food, Drug, and Cosmetic Act, which may rely on the FDA’s finding that a previously approved drug is safe and effective. “There’s an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder,” said FDA Commissioner Scott Gottlieb, M.D. “The introduction of new treatment options has the potential to broaden access for patients.”
 

Related News Articles

Headline
Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., today convened a hearing on “Managing Pain During the Opioid Crisis”…
Headline
The Centers for Medicare…
Headline
The Centers for Medicare…
Insights and Analysis
Also in this weekly roundup of health care news: Providence St. Joseph Health launches population health company; Aetna, others try new approach to educate…
Headline
The Health Resources and Services Administration's Federal Office of Rural Health Policy plans to award about 75 grants of up to $1 million each to expand…
Headline
The White House Office of National Drug Control Policy yesterday released its national drug control strategy, intended to guide federal efforts to reduce the…